(4-(1H-benzo[d]imidazol-2-yl)piperidin-1-yl)(4'-(trifluoromethoxy)-[1,1'-biphenyl]-4-yl)methanone | 1159096-73-7

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: (4-(1H-benzo[d]imidazol-2-yl)piperidin-1-yl)(4'-(trifluoromethoxy)-[1,1'-biphenyl]-4-yl)methanone
• 英文别名: [4-(1H-benzimidazol-2-yl)piperidin-1-yl][4'-(trifluoromethoxy)biphenyl-4-yl]methanone；(4-(1H-benzo[d]imidazol-2-yl)piperidin-1-yl)(4''-(trifluoromethoxy)biphenyl-4-yl)methanone；[4-(1H-benzimidazol-2-yl)piperidin-1-yl]-[4-[4-(trifluoromethoxy)phenyl]phenyl]methanone
• CAS: 1159096-73-7
• 化学式: C₂₆H₂₂F₃N₃O₂
• 分子量: 465.475
• InChiKey: CBKPIAWGRIOYGJ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  6
• 重原子数：
  34
• 可旋转键数：
  4
• 环数：
  5.0
• sp3杂化的碳原子比例：
  0.23
• 拓扑面积：
  58.2
• 氢给体数：
  1
• 氢受体数：
  6

反应信息

• 作为产物：
  描述：

  4-三氟甲氧基-联苯-4-羧酸 、 2-(4-哌啶)-1H-苯并咪唑 在 4-二甲氨基吡啶 、 盐酸-N-乙基-Nˊ-(3-二甲氨基丙基)碳二亚胺 作用下， 以 二氯甲烷 为溶剂， 生成 (4-(1H-benzo[d]imidazol-2-yl)piperidin-1-yl)(4'-(trifluoromethoxy)-[1,1'-biphenyl]-4-yl)methanone
  参考文献：
  名称：

  A new class of 5-HT2B antagonists possesses favorable potency, selectivity, and rat pharmacokinetic properties

  摘要：

  We have been exploring the potential of 5-HT2B antagonists as a therapy for chronic heart failure. To assess the potential of this therapeutic approach, we sought compounds possessing the following attributes: (a) potent and selective antagonism of the 5-HT2B receptor, (b) low impact of serum proteins on potency, and (c) desirable pharmacokinetic properties. This Letter describes our investigation of a biphenyl benzimidazole class of compounds that resulted in 5-HT2B antagonists possessing the above attributes. Improving potency in a human serum albumin shift assay proved to be the most significant SAR discovery. (C) 2009 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2009.02.126

文献信息

• [EN] SEROTONIN 5-HT2B RECEPTOR INHIBITORS<br/>[FR] INHIBITEURS DU RÉCEPTEUR 5-HT2B DE LA SÉROTONINE
  申请人：BOEHRINGER INGELHEIM INT

  公开号：WO2010080357A1

  公开（公告）日：2010-07-15

  Disclosed are Serotonin 5-HT2B receptor inhibitors of the formula I. Also disclosed are methods of making and methods of using these compounds.

  揭示了式I的5-HT2B受体拮抗剂。还公开了制备这些化合物的方法和使用这些化合物的方法。
• Serotonin 5-HT2B Receptor Inhibitors
  申请人：Cogan Derek

  公开号：US20110269742A1

  公开（公告）日：2011-11-03

  Disclosed are Serotonin 5-HT2B receptor inhibitors of the formula I. Also disclosed are methods of making and methods of using these compounds.

  本发明涉及公开了化学式I的血清素5-HT2B受体抑制剂。还公开了制备这些化合物的方法和使用这些化合物的方法。
• SEROTONIN 5-HT2B INHIBITORY COMPOUNDS
  申请人：Zoetis Services LLC

  公开号：EP3947360A1

  公开（公告）日：2022-02-09
• US8609696B2
  申请人：——

  公开号：US8609696B2

  公开（公告）日：2013-12-17
• [EN] SEROTONIN 5-HT2B INHIBITORY COMPOUNDS<br/>[FR] COMPOSÉS INHIBITEURS DE LA SÉROTONINE 5-HT2B
  申请人：ZOETIS SERVICES LLC

  公开号：WO2020198478A1

  公开（公告）日：2020-10-01

  The compounds of the invention, as described herein, are novel serotonin 5-HT2B antagonists useful for the treatment of myxomatous mitral valve degeneration (MMVD), congestive heart failure (CHF), and/or asymptomatic heart failure in animals, preferably canine.